USA - NASDAQ:BIOR - US74319F3055 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to BIOR. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-01-10 | HC Wainwright & Co. | Maintains | Buy |
7 analysts have analysed BIOR and the average price target is 34.68 USD. This implies a price increase of 6096.18% is expected in the next year compared to the current price of 0.5597.
The consensus rating for BIORA THERAPEUTICS INC (BIOR) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.